New narcolepsy treatments are being tested in the clinic, and recently, some of them have made promising strides. How far ...

Q2 2025 Earnings Call Transcript July 29, 2025 Alkermes plc beats earnings expectations. Reported EPS is $0.517, expectations ...

Alkermes (ALKS) reports strong Q2 2025 results with 14% growth, robust finances, and positive Phase II narcolepsy data.

In late November, Georgia beat Georgia Tech in a heart-stopping, eight-overtime classic. In one of the most exciting games of the entire colle ...

In this article, we'll explain how the mslt test helps diagnose narcolepsy, what to expect during the test, and why it's ...

Topline data were announced from two phase 3 trials evaluating oveporexton in patients with narcolepsy type 1.

Alkermes falls 8.8% despite alixorexton hitting key goals in a narcolepsy type 1 study, as cataplexy data stirs investor concerns.

Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist.

Alkermes plc (NASDAQ:ALKS) on Monday released topline results from the randomized double-blind treatment period of the ...

Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts ...

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Alkermes’ investigational drug helped people with a type of narcolepsy stay awake during the day in a mid-stage trial.